Related Experiment Video

Updated: Jul 14, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Efficacy of intravenous midazolam for status epilepticus in childhood

Kitami Hayashi1, Makiko Osawa, Masao Aihara

  • 1Department of Pediatrics, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan. khayashi@tymc.twmu.ac.jp

Pediatric Neurology
|June 15, 2007
PubMed

Insights

Midazolam effectively treats status epilepticus, achieving seizure suppression in 64.5% of patients. Early administration is crucial for optimal outcomes in epilepsy management.

Area of Science:

  • Neurology
  • Clinical Pharmacology
  • Emergency Medicine

Background:

  • Status epilepticus (SE) is a neurological emergency requiring prompt and effective treatment.
  • Intravenous midazolam is a commonly used agent for SE, but its efficacy and safety profile require ongoing evaluation.
  • Understanding treatment delays and their impact on outcomes is critical for improving patient care.

Purpose of the Study:

  • To evaluate the efficacy and safety of intravenous midazolam for treating status epilepticus.
  • To identify factors influencing treatment outcomes, including timing of administration.
  • To assess adverse events associated with midazolam therapy in SE.

Main Methods:

  • Retrospective multicenter study of 358 inpatients treated with intravenous midazolam for status epilepticus.
  • Data collected on patient demographics, underlying disorders, midazolam dosage (bolus and infusion), and treatment outcomes.
  • Analysis of seizure suppression rates and adverse events, with a focus on the time from seizure onset to treatment initiation.

Main Results:

  • Overall seizure suppression was achieved in 231 cases (64.5%).
  • Midazolam bolus injection was effective in 56.6% of cases where it was assessed.
  • Treatment effectiveness was reduced when midazolam was initiated more than 3 hours after seizure onset, particularly in epilepsy patients.

Conclusions:

  • Intravenous midazolam is a highly effective treatment for status epilepticus.
  • Early administration of midazolam is associated with better seizure suppression outcomes.
  • Adverse events were consistent with known profiles, and no deaths were attributed to midazolam.

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...